93 related articles for article (PubMed ID: 35327440)
1. Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy.
Cheung LC; Aya-Bonilla C; Cruickshank MN; Chiu SK; Kuek V; Anderson D; Chua GA; Singh S; Oommen J; Ferrari E; Hughes AM; Ford J; Kunold E; Hesselman MC; Post F; Faulk KE; Breese EH; Guest EM; Brown PA; Loh ML; Lock RB; Kees UR; Jafari R; Malinge S; Kotecha RS
Leukemia; 2023 Jan; 37(1):61-71. PubMed ID: 36380143
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Evaluation of Carfilzomib for Infant
Cheung LC; de Kraa R; Oommen J; Chua GA; Singh S; Hughes AM; Ferrari E; Ford J; Chiu SK; Stam RW; Kees UR; Malinge S; Kotecha RS
Front Oncol; 2021; 11():631594. PubMed ID: 33937032
[TBL] [Abstract][Full Text] [Related]
3. Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631.
Faulk KE; Kairalla JA; Dreyer ZE; Carroll AJ; Heerema NA; Devidas M; Carroll WL; Raetz EA; Loh ML; Hunger SP; Borowitz M; Wang C; Guest E; Brown PA
Pediatr Blood Cancer; 2023 May; ():e30467. PubMed ID: 37259259
[TBL] [Abstract][Full Text] [Related]
4. High-throughput screening as a drug repurposing strategy for poor outcome subgroups of pediatric B-cell precursor Acute Lymphoblastic Leukemia.
Oikonomou A; Valsecchi L; Quadri M; Watrin T; Scharov K; Procopio S; Tu JW; Vogt M; Savino AM; Silvestri D; Valsecchi MG; Biondi A; Borkhardt A; Bhatia S; Cazzaniga G; Fazio G; Bardini M; Palmi C
Biochem Pharmacol; 2023 Nov; 217():115809. PubMed ID: 37717691
[TBL] [Abstract][Full Text] [Related]
5. Azacitidine as epigenetic priming for chemotherapy is safe and well-tolerated in infants with newly diagnosed KMT2A-rearranged acute lymphoblastic leukemia: Children's Oncology Group trial AALL15P1.
Guest EM; Kairalla JA; Devidas M; Hibbitts E; Carroll AJ; Heerema NA; Kubaney HR; August MA; Ramesh S; Yoo B; Farooqi MS; Pauly MG; Wechsler DS; Miles RR; Reid JM; Kihei CD; Gore L; Raetz EA; Hunger SP; Loh ML; Brown PA
Haematologica; 2024 Jun; ():. PubMed ID: 38867582
[TBL] [Abstract][Full Text] [Related]
6. Duplex Sequencing Uncovers Recurrent Low-frequency Cancer-associated Mutations in Infant and Childhood
Pilheden M; Ahlgren L; Hyrenius-Wittsten A; Gonzalez-Pena V; Sturesson H; Hansen Marquart HV; Lausen B; Castor A; Pronk CJ; Barbany G; Pokrovskaja Tamm K; Fogelstrand L; Lohi O; Norén-Nyström U; Asklin J; Chen Y; Song G; Walsh M; Ma J; Zhang J; Saal LH; Gawad C; Hagström-Andersson AK
Hemasphere; 2022 Oct; 6(10):e785. PubMed ID: 36204688
[TBL] [Abstract][Full Text] [Related]
7. Modelling acquired resistance to DOT1L inhibition exhibits the adaptive potential of KMT2A-rearranged acute lymphoblastic leukemia.
Schneider P; Crump NT; Arentsen-Peters STCJM; Smith AL; Hagelaar R; Adriaanse FRS; Bos RS; de Jong A; Nierkens S; Koopmans B; Milne TA; Pieters R; Stam RW
Exp Hematol Oncol; 2023 Sep; 12(1):81. PubMed ID: 37740239
[TBL] [Abstract][Full Text] [Related]
8. Functional relevance of circRNA aberrant expression in pediatric acute leukemia with KMT2A::AFF1 fusion.
Tretti Parenzan C; Molin AD; Longo G; Gaffo E; Buratin A; Cani A; Boldrin E; Serafin V; Guglielmelli P; Vannucchi AM; Cazzaniga G; Biondi A; Locatelli F; Meyer LH; Buldini B; Te Kronnie G; Bresolin S; Bortoluzzi S
Blood Adv; 2024 Mar; 8(5):1305-1319. PubMed ID: 38029383
[TBL] [Abstract][Full Text] [Related]
9. KMT2A oncoproteins induce epigenetic resistance to targeted therapies.
Janssens DH; Duran M; Otto DJ; Kirkey D; Yi JS; Meshinchi S; Sarthy JF; Ahmad K; Henikoff S
bioRxiv; 2023 Dec; ():. PubMed ID: 38234854
[TBL] [Abstract][Full Text] [Related]
10. Erratum: Clinical Implications of Minimal Residual Disease Detection in Infants With
J Clin Oncol; 2023 Oct; 41(30):4825. PubMed ID: 37699172
[No Abstract] [Full Text] [Related]
11. Fusion and flow: refining risk prediction in
Conneely SE; Rau RE
Transl Pediatr; 2023 Dec; 12(12):2099-2102. PubMed ID: 38197101
[No Abstract] [Full Text] [Related]
12. Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia.
Burmeister T; Ströh AS; Kehden B; Trautmann H; Meyer C; Marschalek R; Larghero P; Schwartz S; Steffen B; Spriewald B; Heinicke T; Jäkel N; Westermann J; Nachtkamp K; Viardot A; Topp MS; Neumann M; Baldus CD; Gökbuget N; Brüggemann M
Leukemia; 2024 Mar; ():. PubMed ID: 38519799
[No Abstract] [Full Text] [Related]
13. KMT2A-rearranged B-lymphoblastic leukemia/lymphoma with surface light chain restriction and lacking immature markers.
Fu L; Gong S
Blood; 2023 Dec; 142(25):2220. PubMed ID: 38127411
[No Abstract] [Full Text] [Related]
14. Detection of Genomic Structural Variations Associated with Drug Sensitivity and Resistance in Acute Leukemia.
Finlay D; Murad R; Hong K; Lee J; Pang AWC; Lai CY; Clifford B; Burian C; Mason J; Hastie AR; Yin J; Vuori K
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254907
[TBL] [Abstract][Full Text] [Related]
15. KRAS G12 mutations as adverse prognostic factors in KMT2A-rearranged acute myeloid leukemia.
Iyoda S; Yoshida K; Shoji K; Ito N; Tanaka M; Nannya Y; Yamato G; Tsujimoto S; Shiba N; Hayashi Y; Shiozawa Y; Shiraishi Y; Chiba K; Okada A; Tanaka H; Miyano S; Koga Y; Goto H; Moritake H; Terui K; Ito E; Kiyokawa N; Tomizawa D; Taga T; Tawa A; Takita J; Nishikori M; Adachi S; Ogawa S; Matsuo H
Leukemia; 2024 Apr; ():. PubMed ID: 38632314
[No Abstract] [Full Text] [Related]
16. Unraveling KMT2A-rearranged ALL.
Shimony S; Luskin MR
Blood; 2023 Nov; 142(21):1764-1766. PubMed ID: 37995105
[No Abstract] [Full Text] [Related]
17. Convergent TP53 loss and evolvability in cancer.
Mansur MB; Greaves M
BMC Ecol Evol; 2023 Sep; 23(1):54. PubMed ID: 37743495
[TBL] [Abstract][Full Text] [Related]
18. High-Throughput Drug Library Screening in Primary
Wander P; Arentsen-Peters STCJM; Vrenken KS; Pinhanҫos SM; Koopmans B; Dolman MEM; Jones L; Garrido Castro P; Schneider P; Kerstjens M; Molenaar JJ; Pieters R; Zwaan CM; Stam RW
Biomedicines; 2022 Mar; 10(3):. PubMed ID: 35327440
[TBL] [Abstract][Full Text] [Related]
19. CRISPR-Cas9 Library Screening Identifies Novel Molecular Vulnerabilities in
Schneider P; Wander P; Arentsen-Peters STCJM; Vrenken KS; Rockx-Brouwer D; Adriaanse FRS; Hoeve V; Paassen I; Drost J; Pieters R; Stam RW
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686014
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
